Overview

Enzalutamide & Dutasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.

Status:
Active, not recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Determine the effect of enzalutamide and dutasteride on the time to prostatic-specific antigen level increase in patients age 65 or older.
Phase:
Phase 2
Details
Lead Sponsor:
University of Rochester
Treatments:
Dutasteride